|
1
|
Shiota C, Woo JT, Lindner J, Shelton KD
and Magnuson MA: Multiallelic disruption of the rictor gene in mice
reveals that mTOR complex 2 is essential for fetal growth and
viability. Dev Cell. 11:583–589. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu WK, Lee CW, Cho CH, Chan FK, Yu J and
Sung JJ: RNA interference targeting raptor inhibits proliferation
of gastric cancer cells. Exp Cell Res. 317:1353–1358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
|
|
4
|
Hudes G, Carducci M, Tomczak P, et al:
Temsirolimus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar
|
|
5
|
Houghton PJ: Everolimus. Clin Cancer Res.
16:1368–1372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shor B, Zhang WG, Toral-Barza L, et al: A
new pharmacologic action of CCI-779 involves FKBP12-independent
inhibition of mTOR kinase activity and profound repression of
global protein synthesis. Cancer Res. 68:2934–2943. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noh WC, Mondesire WH, Peng J, et al:
Determinants of rapamycin sensitivity in breast cancer cells. Clin
Cancer Res. 10:1013–1023. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang WG, Watkins G, Lane J, et al:
Prognostic value of rho GTPases and rho guanine nucleotide
dissociation inhibitors in human breast cancers. Clin Cancer Res.
9:6432–6440. 2003.PubMed/NCBI
|
|
9
|
Vezina C, Kudelski A and Sehgal SN:
Rapamycin (AY-22,989), a new antifungal antibiotic. I Taxonomy of
the producing streptomycete and isolation of the active principle.
J Antibiot (Tokyo). 28:721–726. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bjornsti MA and Houghton PJ: The TOR
pathway: a target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brown EJ, Albers MW, Shin TB, et al: A
mammalian protein targeted by G1-arresting rapamycin-receptor
complex. Nature. 369:756–758. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao X, Zhang Y, Arrazola P, et al: Tsc
tumour suppressor proteins antagonize amino-acid-TOR signalling.
Nat Cell Biol. 4:699–704. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Manning BD and Cantley LC: Rheb fills a
GAP between TSC and TOR. Trends Biochem Sci. 28:573–576. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuen HF, Chan KK, Grills C, et al: Ran is
a potential therapeutic target for cancer cells with molecular
changes associated with activation of the PI3K/Akt/mTORC1 and
Ras/MEK/ERK pathways. Clin Cancer Res. 18:380–391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inoki K, Ouyang H, Zhu T, et al: TSC2
integrates Wnt and energy signals via a coordinated phosphorylation
by AMPK and GSK3 to regulate cell growth. Cell. 126:955–968. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng M, Wang YH, Wu XN, et al:
Inactivation of Rheb by PRAK-mediated phosphorylation is essential
for energy-depletion-induced suppression of mTORC1. Nat Cell Biol.
13:263–272. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toschi A, Lee E, Thompson S, et al:
Phospholipase D-mTOR requirement for the Warburg effect in human
cancer cells. Cancer Lett. 299:72–79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guertin DA and Sabatini DM: The
pharmacology of mTOR inhibition. Sci Signal. 2:pe242009.PubMed/NCBI
|
|
20
|
Shoji K, Oda K, Kashiyama T, et al:
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor,
NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial
carcinomas. PLoS One. 7:e374312012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sarbassov DD, Ali SM, Kim DH, et al:
Rictor, a novel binding partner of mTOR, defines a
rapamycin-insensitive and raptor-independent pathway that regulates
the cytoskeleton. Curr Biol. 14:1296–1302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McDonald PC, Oloumi A, Mills J, et al:
Rictor and integrin-linked kinase interact and regulate Akt
phosphorylation and cancer cell survival. Cancer Res. 68:1618–1624.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mokbel K: The role of telomerase in breast
cancer. Eur J Surg Oncol. 26:509–514. 2000. View Article : Google Scholar
|
|
24
|
Elkak A, Mokbel R, Wilson C, Jiang WG,
Newbold RF and Mokbel K: hTERT mRNA expression is associated with a
poor clinical outcome in human breast cancer. Anticancer Res.
26:4901–4904. 2006.PubMed/NCBI
|
|
25
|
Zhou C, Gehrig PA, Whang YE and Boggess
JF: Rapamycin inhibits telomerase activity by decreasing the hTERT
mRNA level in endometrial cancer cells. Mol Cancer Ther. 2:789–795.
2003.PubMed/NCBI
|
|
26
|
Bu X, Jia F, Wang W, Guo X, Wu M and Wei
L: Coupled down-regulation of mTOR and telomerase activity during
fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC
Cancer. 7:2082007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamada O, Ozaki K, Akiyama M and Kawauchi
K: JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase
transcriptionally and posttranslationally in ATL cells. Mol Cancer
Ther. 11:1112–1121. 2012. View Article : Google Scholar : PubMed/NCBI
|
